Background: Although prior studies showed metformin could reduce gastric cancer (GC) 
Conclusions:
Metformin use was associated with a lower GC risk among H. pylorieradicated diabetic patients in a duration-and dose-response manner, which was independent of HbA1c level.
INTRODUCTION
Gastric cancer (GC) is the fifth commonest cancer and the third leading cause of cancerrelated mortality worldwide.(1) Helicobacter pylori (H. pylori) infection is the major risk factor for GC (2) . However, H. pylori eradication could only reduce GC risk by approximately 40% (3) (4) (5) . Apart from H. pylori, diabetes mellitus (DM) has been reported to increase GC risk by approximately 20%. (6) As DM is a very prevalent medical condition with more than 12% of adult population being affected,(7) the burden of GC cases attributed to DM could be substantial.
Metformin, a biguanide, is frequently used to treat DM. Apart from its effect on glycemic control, metformin has anti-cancer effect associated with insulin sensitization, reducing hyperinsulinemia and insulin-growth factor (IGF) production, both of which shown to enhance proliferation of cancer cells that express IGF receptors. (8) Metformin also activates AMP-activated protein kinase (AMPK) which suppresses cancer cell growth by inhibiting the mammalian target of rapamycin pathway. (9) The chemopreventive role of metformin in GC, however, remains controversial. While no association between metformin use and GC was reported by some studies, (10, 11) others suggested a protective effect with varying effect estimates. (12) (13) (14) (15) (16) A recent meta-analysis (17) concluded that metformin decreased GC risk by 24% but there was a statistically significant heterogeneity among studies. More importantly, other important risk factors of GC including H. pylori infection and DM severity have not been adequately addressed in previous studies, potentially undermining the role of metformin on GC prevention. (17) As H. pylori is the most important risk factor of GC, failure to stratify patients according to H. pylori status will affect the true effect estimate of metformin on GC development. Moreover, GC risk was shown to be higher among individuals with higher hemoglobin A1c (HbA1c) levels (18) . The beneficial effect of metformin on reducing GC could be mediated via improving DM control rather than the proposed anti-cancer mechanisms.
With the use of a large cohort of diabetic patients who had received H. pylori eradication therapy, we aimed to investigate the potential chemopreventive effect of metformin on GC in diabetic patients who had received H. pylori eradication therapy, and whether higher HbA1c level was associated with an increased GC risk.
METHODS

Data source
This was a territory-wide cohort study using data retrieved from the Clinical Data Analysis and Reporting System (CDARS) of the Hong Kong Hospital Authority. The Hospital Authority is the governing body of all public hospitals and clinics in Hong Kong with a population of 7.3 million, and a 90% coverage of all primary, secondary and tertiary care during the study period (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) . (19) Patient's data including demographics, diagnoses, drug dispensing records, procedures and laboratory results, hospitalization, attendance of outpatient clinics and emergency departments, and death are all accessible in the CDARS. (20) (21) (22) (23) (24) (25) Diagnoses are coded in accordance with the International Classification of Diseases, Ninth Revision (ICD-9). Prior studies using this electronic registry database showed high coding accuracy with positive and negative predictive values of > 90. (21, 26) Individuals' information is anonymized with a unique reference key to protect patient's confidentiality. The study was approved by the Institutional Review Board of the University of Hong Kong and the West Cluster of Hospital Authority, Hong Kong (reference no: UW 16-545).
Study Subjects
All adult patients aged 18 years or above with a baseline diagnosis of DM who were 
Study Outcome
Gastric adenocarcinoma after H. pylori eradication therapy was identified by the ICD-9 coding (Supplementary Table 1 ). The validation of the GC diagnosis and final H. pylori status of these cancer patients had been validated in our previous studies, with 100% accuracy. (30) The observation period started from the first date of H. pylori therapy prescription (i.e. index date), and censored at GC diagnosis, death or end of study (December 2015) . The earliest date of hospitalization for cancer workup or treatment was regarded as the GC diagnosis date.
Metformin, insulin and other covariates
We defined metformin use as more than 180-day use [as proposed by Kim et al (13) 
Statistical analyses
All statistical analyses were performed using R version 3. Propensity score (PS) adjustment was used to control for selection bias due to different baseline characteristics. The PS was estimated by multivariable logistic regression based on the aforementioned covariates, and represents the probability of prescribing metformin to an individual given the covariates. As such, any difference in GC risk would be due to metformin effect only. The PS distributions between metformin and non-metformin groups were compared graphically, showing no statistically significant areas of non-overlap which would otherwise violate the assumption of PS analysis (Supplementary Figure 2) 
(41).
The primary analysis was Cox regression with PS adjustment. The PS adjusted absolute difference in GC risk between metformin and non-metformin users was calculated as follows: (adjusted HR -1) x (crude incidence rate of GC in non-metformin users). (42) Sensitivity analysis was conducted to assess robustness of the results, including multivariable analysis, PS adjustment after trimming of individuals in the non-overlapping parts of PS distribution,(43) PS weighting by inverse probability treatment weighting (IPTW) with stabilisation, (44) and PS matching without replacement in a 1:1 ratio. (45) The description of these PS analysis methods was detailed in Supplementary Table 2 .
Standardised difference was used to assess the balance of the covariates between the two groups before and after IPTW and PS matching, and a value of below 0.2 indicated a negligible difference.(46) Supplementary Table 3 shows that most of the covariates were balanced after either IPTW or PS matching. Supplementary Figures 2 and 3 also show that PS distriubtion between the two groups became largely similar after PS matching.
Similar statistical analyses were performed to determine the association between insulin use and GC. A two-sided p-value of < 0.05 was used to define statistical significance.
The R packages 'survival' and 'MatchIt' were used for Cox regression analysis and PS matching, respectively. 
RESULTS
Patient characteristics
Effect of metformin, insulin, and HbA1c on gastric cancer risk
The median duration of metformin use was 5. 
DISCUSSION
In this territory-wide cohort study including more than 7,200 diabetic patients who had H.
pylori eradicated, we showed that metformin use was associated with a 51% reduction in GC risk, with a clear dose-and duration-gradient association. Since GC risk was found to be 20%
higher among diabetic patients(6) and eradication of H. pylori could only reduce GC risk by about 40%, (3, 4) there is a genuine need to identify novel chemopreventive agents for this specific group of high-risk patients. average HbA1c level into analysis, our study not only considered the baseline HbA1c level but also the dynamics of DM control throughout the follow-up so that a more precise effect estimate could be derived. In our study, a higher time-weighted average HbA1c level of ≥7%
was not an independent risk factor for GC after H. pylori eradication. In contrary, a Japanese population-based cohort study showed that a higher HbA1c level acted synergistically with H.
pylori infection in increasing GC risk (18) . Notably, their study cohort differed from our current cohort of H. pylori-eradicated subjects, and no adjustments were made on the use of concurrent medications that could modulate GC risk, such as aspirin/NSAIDs(32), statins (34) and PPIs (35) .
We found that HbA1c levels were actually higher among metformin users, possibly related to the poor glycemic control necessitating metformin use. Yet, GC risk was statistically significantly lower in the metformin group. Hence, our findings support the biological mechanisms underlying metformin in preventing GC, which is not mediated through improving glycemic control. Notably, although IGFs have been linked to GC development(40), insulin treatment was not associated with an increased GC risk in this study.
The duration-and dose-response association observed further strengthened the possible chemopreventive effect of metformin on GC. A longer duration of metformin use was associated with a lower GC risk, which was consistent with the study by Kim et al showing the chemopreventive effect was only evident after ≥3 years of metformin use. (13) The strength of our study is the use of a comprehensive electronic public healthcare database that included drug prescription and dispensing records, reducing selection and information biases of observational studies.(32) The long follow-up duration (a median of 7 years) also enables the assessment of GC with a long lag time. The robustment of the result is verified by the consistency from sensitivity analysis using various PS analysis methods which adjusted for a wide array of covariates. Notably, metformin users had more cormobidities than non-metformin users ( Table 1) . Given than all these covariates are potential risk factors of GC, the protective effects of statin against GC could only be underestimated. In conclusion, our territory-wide study showed that among diabetic patients who had H. pylori-eradicated, metformin use was associated with a statistically significantly lower GC risk in a duration-and dose-response manner. This cancer protective effect was independent of glycemic control. 
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